The Systemic Sclerosis Market Size was valued at approximately USD 1,937 million in 2025 and is anticipated to grow with a significant CAGR of 3.6% to reach around USD 2,660 million by 2034 during the study period (2020-2034), according to DelveInsight’s comprehensive market analysis.
DelveInsight’s “Systemic Sclerosis Market Insight, Epidemiology, and Market Forecast 2034” analysis delivers extensive intelligence regarding the current clinical development landscape and expansion opportunities throughout the Systemic Sclerosis therapeutic market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Access a Complimentary Sample PDF Report for additional information regarding Systemic Sclerosis Market Assessment- https://www.delveinsight.com/report-store/systemic-sclerosis-market
Primary Insights from the Systemic Sclerosis Market Analysis:
- In 2024, the United States represented the largest share of the systemic sclerosis market within the 7MM, accounting for nearly 75% of the total market size.
- Among EU4 and the UK, Italy accounted for the largest Systemic Sclerosis Market Size, whereas Spain accounted for the smallest market size in 2023.
- Leading Systemic Sclerosis organizations developing therapeutics in the market include Genentech, Kyowa Kirin, GSK, AstraZeneca, Amgen (Horizon Therapeutics), Mitsubishi Tanabe Pharma, Roche (Genentech), Kiniksa Pharmaceuticals, Boehringer Ingelheim, aTyr Pharma, Kyorin Pharmaceutical, Cumberland Pharmaceuticals, among others.
- According to DelveInsight’s 2024 analysis, the 7MM accounted for nearly 231,200 diagnosed prevalent systemic sclerosis cases, with numbers expected to rise over the forecast period.
- In the current market, the majority of the share was accounted for by vasoactive drugs in the US, which was around USD 1,180 million in 2024.
- RITUXAN and ACTEMRA, whose primary patents have expired, face biosimilar competition in several indications, impacting their overall sales significantly.
- In June , aTyr Pharma announced interim Phase II EFZOCONNECT trial results for efzofitimod, demonstrating favorable safety and tolerability, along with stable or improved mRSS across all patients, meaningful clinical benefits in diffuse SSc-ILD, and promising biomarker responses.
Discover more about Systemic Sclerosis therapeutic market opportunities @ Systemic Sclerosis Market Trends
Systemic Sclerosis Disease Overview
Systemic Sclerosis (SSc), also known as scleroderma, represents a rare autoimmune connective tissue disorder characterized by hardening and tightening of the skin and connective tissues. This condition occurs when the immune system attacks the body’s own tissues, resulting in fibrosis (excessive tissue buildup), vascular abnormalities, and organ dysfunction. The disease can affect the skin, lungs, heart, kidneys, and digestive tract, causing symptoms including skin thickening, Raynaud’s phenomenon, difficulty swallowing, shortness of breath, and fatigue.
Marketed Systemic Sclerosis Therapeutics
Approved therapeutics for systemic sclerosis include:
OFEV (nintedanib): Boehringer Ingelheim
Nintedanib belongs to a class of medications called kinase inhibitors and functions by blocking the action of enzymes involved in causing fibrosis. It is utilized to slow the rate of decline in lung function in individuals with systemic sclerosis-associated interstitial lung disease, a condition characterized by lung scarring that is often fatal. In September 2019, the US FDA approved OFEV capsules to slow the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease. The company holds Orphan drug exclusivity of OFEV until 2026.
ACTEMRA (tocilizumab): Roche
ACTEMRA represents an anti-IL-6 receptor biologic and is available in both intravenous (IV) and subcutaneous (SC) formulations. ACTEMRA SC is approved in the US to slow the rate of pulmonary function decline in adult patients with systemic sclerosis-associated interstitial lung disease. This therapeutic is part of a co-development agreement with Chugai Pharmaceutical. In March 2021, the US FDA approved ACTEMRA SC injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease. In September 2023, Roche withdrew its application to use ROACTEMRA in Europe for the same indication.
RITUXAN (rituximab): Zenyaku Kogyo/Chugai Pharmaceutical
Zenyaku and Chugai obtained approval from the Japanese MHLW for an anti-CD20 monoclonal antibody, RITUXAN (rituximab), for systemic sclerosis management.
Investigational Systemic Sclerosis Therapeutics Under Development Include:
LUMICEF (brodalumab/KHK-4827): Kyowa Kirin
LUMICEF represents a recombinant, human IgG monoclonal antibody to the interleukin (IL)-17A receptor, the engagement of which results in the release of pro-inflammatory mediators. The binding of the monoclonal antibody blocks the interaction of IL-17A with its receptor and thus decreases inflammatory pathways involved in immune-mediated cell injury. In December 2019, LUMICEF was designated as an Orphan Drug by the Ministry of Health, Labour and Welfare (MHLW) for systemic sclerosis and is subject to Priority Review. The application of LUMICEF is under review in Japan for systemic sclerosis. In December 2021, Kyowa Kirin announced that the company filed an application to the MHLW for a partial change of approved indication of LUMICEF for systemic sclerosis in Japan.
BENLYSTA (belimumab): GSK
BENLYSTA represents a recombinant, fully human monoclonal antibody that is approved by the US FDA for the treatment of systemic lupus erythematosus. It binds to soluble human BLyS and inhibits its biological activity, resulting in apoptosis of B lymphocytes and decreased autoantibody production. In February 2023, GSK announced that the US FDA granted an Orphan Drug Designation to BENLYSTA for the potential treatment of systemic sclerosis. As per GSK’s first quarter 2024 clinical trial appendix, for the BLISSc-ILD Phase III trial, the data is anticipated in 2026+.
SAPHNELO (anifrolumab): AstraZeneca
SAPHNELO represents a first-in-class, fully human monoclonal antibody. It disrupts the Type I interferon auto-amplification loop that can trigger the loss of immune tolerance and autoimmunity. Additionally, it partially inhibits the upregulation of costimulatory molecules and the production of pro-inflammatory cytokines by plasmacytoid dendritic cells (pDCs). SAPHNELO was granted Orphan Drug Designation by the US FDA for the treatment of systemic sclerosis in 2013. As per AstraZeneca’s first quarter report of 2024, the first patient commenced dosing in the fourth quarter of 2023, with data anticipated >2025 in the Phase III DAISY clinical trial.
Additional Pipeline Candidates:
- UPLIZNA (inebilizumab/MT-0551): Amgen (Horizon Therapeutics)/Mitsubishi Tanabe Pharma
- Vixarelimab (RG6536): Roche (Genentech)/Kiniksa Pharmaceuticals
- Efzofitimod: aTyr Pharma/Kyorin Pharmaceutical
- KYV 101: Kyverna Therapeutics
- CABA-201: Cabaletta Bio
Explore investigational therapeutic opportunities in systemic sclerosis @ Systemic Sclerosis Pipeline Analysis
Leading Organizations in the Systemic Sclerosis Therapeutics Landscape
Primary organizations developing therapeutics for Systemic Sclerosis management include Genentech, Kyowa Kirin, GSK, AstraZeneca, Amgen (Horizon Therapeutics), Mitsubishi Tanabe Pharma, Roche (Genentech), Kiniksa Pharmaceuticals, Boehringer Ingelheim, aTyr Pharma, Kyorin Pharmaceutical, Cumberland Pharmaceuticals, among others.
Systemic Sclerosis Epidemiology Analysis
- Based on DelveInsight’s assessment in 2024, the 7MM had approximately 231,200 diagnosed prevalent cases of systemic sclerosis. These cases are projected to increase during the forecast period.
- Among EU4 and the UK, Italy had the highest number of diagnosed prevalent cases of systemic sclerosis, while Spain had the lowest number of diagnosed prevalent cases.
- It is observed that systemic sclerosis occurs majorly in the age group of 40–69 years.
- Analysis of age-specific data in the US indicates that systemic sclerosis was least prevalent among individuals aged 39 years or younger, with the highest number of diagnosed cases observed in those aged between 40 and 69 years.
Systemic Sclerosis Market Growth Drivers
- Rising Prevalence and Diagnosis of Systemic Sclerosis: The increasing number of diagnosed cases, particularly in the 40–69 age group, is driving demand for effective therapies. Enhanced awareness among healthcare professionals and improved diagnostic techniques are contributing to earlier detection.
- Growing Awareness and Education Initiatives: Patient awareness campaigns and educational programs for physicians are helping identify and manage systemic sclerosis more effectively, boosting market growth.
- Launch of Novel and Targeted Therapies: Recent approvals and emerging therapies such as nintedanib (OFEV), tocilizumab (ACTEMRA), and rituximab (RITUXAN) are expanding treatment options. Innovative drug development targeting fibrosis and immune modulation is expected to revolutionize SSc management.
- Supportive Regulatory Frameworks: Orphan drug designations and fast-track approvals by regulatory bodies like the FDA and EMA are accelerating the availability of therapies for this rare autoimmune condition, promoting market expansion.
- Rising Investment in R&D and Clinical Trials: Increased research activities, clinical trials for novel molecules, and combination therapies are driving pipeline growth, offering hope for better outcomes and attracting investor interest in the systemic sclerosis market.
Stay updated on ongoing developments influencing the systemic sclerosis treatment ecosystem @ Systemic Sclerosis Market Drivers and Barriers
Scope of Systemic Sclerosis Report
- Study Period: 2020 to 2034
- Coverage: Global
- Key Organizations: Genentech, Kyowa Kirin, GSK, AstraZeneca, Amgen (Horizon Therapeutics), Mitsubishi Tanabe Pharma, Roche (Genentech), Kiniksa Pharmaceuticals, Boehringer Ingelheim, aTyr Pharma, Kyorin Pharmaceutical, Cumberland Pharmaceuticals, among others
- Key Therapeutic Candidates: LUMICEF (brodalumab/KHK-4827), BENLYSTA (belimumab), SAPHNELO (anifrolumab), UPLIZNA (inebilizumab/MT-0551), Vixarelimab, Efzofitimod, and additional therapeutics
- Market Segmentation: Total Market Size, Market Size by Therapies, Market Size by Class
For extensive intelligence regarding market developments and therapeutic opportunities, access the comprehensive analysis @ Systemic Sclerosis Market Forecast
Table of Contents
1. Systemic Sclerosis Market Report Introduction
2. Executive Summary for Systemic Sclerosis
3. SWOT analysis of Systemic Sclerosis
4. Systemic Sclerosis Patient Share (%) Overview at a Glance
5. Systemic Sclerosis Market Overview at a Glance
6. Systemic Sclerosis Disease Background and Overview
7. Systemic Sclerosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Systemic Sclerosis
9. Systemic Sclerosis Current Treatment and Medical Practices
10. Systemic Sclerosis Unmet Needs
11. Systemic Sclerosis Emerging Therapies
12. Systemic Sclerosis Market Outlook
13. Country-Wise Systemic Sclerosis Market Analysis (2020–2034)
14. Systemic Sclerosis Market Access and Reimbursement of Therapies
15. Systemic Sclerosis Market Drivers
16. Systemic Sclerosis Market Barriers
17. Systemic Sclerosis Appendix
18. Systemic Sclerosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight represents a premier healthcare-specialized market research and consulting organization delivering high-quality market intelligence and strategic analysis to support informed decision-making for clients. Supported by a team of seasoned industry professionals and extensive expertise in life sciences and healthcare domains, we deliver tailored research solutions and strategic insights to clients worldwide. Partner with us to access high-quality, precise, and real-time intelligence for maintaining competitive advantage.
